دورية أكاديمية
An observational study of hospitalized COVID-19 patients with cancer in San Diego county.
| العنوان: | An observational study of hospitalized COVID-19 patients with cancer in San Diego county. |
|---|---|
| المؤلفون: | Hermel DJ; Division of Hematology & Oncology, Scripps Clinic, La Jolla, CA 92037, USA., Cham J; Division of Hematology & Oncology, Scripps Clinic, La Jolla, CA 92037, USA., Spierling Bagsic SR; Division of Hematology & Oncology, Scripps Clinic, La Jolla, CA 92037, USA., Hong LK; Division of Hematology & Oncology, Scripps Clinic, La Jolla, CA 92037, USA., Costantini CL; Division of Hematology & Oncology, Scripps Clinic, La Jolla, CA 92037, USA., Mason JR; Division of Hematology & Oncology, Scripps Clinic, La Jolla, CA 92037, USA., Saven A; Division of Hematology & Oncology, Scripps Clinic, La Jolla, CA 92037, USA., Sigal DS; Division of Hematology & Oncology, Scripps Clinic, La Jolla, CA 92037, USA. |
| المصدر: | Future oncology (London, England) [Future Oncol] 2022 Feb; Vol. 18 (6), pp. 719-725. Date of Electronic Publication: 2022 Feb 02. |
| نوع المنشور: | Journal Article; Observational Study |
| اللغة: | English |
| بيانات الدورية: | Publisher: Future Medicine Ltd Country of Publication: England NLM ID: 101256629 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1744-8301 (Electronic) Linking ISSN: 14796694 NLM ISO Abbreviation: Future Oncol Subsets: MEDLINE |
| أسماء مطبوعة: | Original Publication: London : Future Medicine Ltd., c2005- |
| مواضيع طبية MeSH: | COVID-19/*complications , COVID-19/*mortality , Neoplasms/*complications , Neoplasms/*drug therapy, Aged ; Aged, 80 and over ; Antineoplastic Agents/therapeutic use ; California/epidemiology ; Female ; Hospitalization ; Humans ; Immune Checkpoint Inhibitors/therapeutic use ; Immunologic Factors/therapeutic use ; Lung Neoplasms/complications ; Male ; Middle Aged ; Molecular Targeted Therapy ; Patient Acuity ; Retrospective Studies ; SARS-CoV-2 |
| مستخلص: | Aim: To delineate clinical correlates of COVID-19 infection severity in hospitalized patients with malignancy. Methods: The authors conducted a retrospective review of all hospitalized patients with a hematologic and/or solid tumor malignancy presenting to the authors' institution between 1 March 2020 and 5 January 2021, with a laboratory confirmed diagnosis of COVID-19. Univariate and multivariate logistic regression analyses were used to determine associations between specific severity outcomes and clinical characteristics. Results: Among 2771 hospitalized patients with COVID-19, 246 (8.88%) met inclusion criteria. Patients who were actively receiving treatment had an increased rate of death following admission (odds ratio [OR]: 2.7). After adjusting for significant covariates, the odds ratio increased to 4.4. Patients with cancer involvement of the lungs had a trend toward increased odds of death after adjusting for covariates (OR: 2.3). Conclusions: Among COVID-19 positive hospitalized cancer patients, systemic anti-cancer therapy was associated with significantly increased odds of mortality. |
| References: | Ann Oncol. 2020 Jul;31(7):894-901. (PMID: 32224151) Lancet. 2020 Jun 20;395(10241):1919-1926. (PMID: 32473682) Eur J Cancer. 2020 Nov;139:43-50. (PMID: 32971510) Nat Cancer. 2020 Oct;1(10):946-964. (PMID: 35121872) Lancet Reg Health Eur. 2021 Sep;8:100158. (PMID: 34308411) J Clin Oncol. 2020 Oct 20;38(30):3538-3546. (PMID: 32795225) Lancet Oncol. 2020 Mar;21(3):335-337. (PMID: 32066541) Future Sci OA. 2021 Jun 12;7(8):FSO735. (PMID: 34290882) Front Oncol. 2020 Nov 20;10:595804. (PMID: 33330085) BMJ. 2020 May 22;369:m1985. (PMID: 32444460) Nature. 2020 Mar;579(7798):265-269. (PMID: 32015508) Br J Cancer. 2021 May;124(11):1777-1784. (PMID: 33767417) Cancer Discov. 2020 Jun;10(6):783-791. (PMID: 32345594) Cancer Discov. 2020 Jul;10(7):935-941. (PMID: 32357994) J Hematol Oncol. 2020 Jun 10;13(1):75. (PMID: 32522278) JAMA Intern Med. 2021 Apr 1;181(4):478-479. (PMID: 33351074) |
| فهرسة مساهمة: | Keywords: COVID-19; SARS-CoV-2; cancer; hematologic malignancy; lung cancer; lung metastasis; systemic anti-cancer therapy Local Abstract: [plain-language-summary] Plain language summary Though cancer is a biologically heterogenous disease with a wide spectrum of clinical features and behavior, accumulating evidence suggests that cancer patients are at greater susceptibility to COVID-19 infection and more likely to experience morbidity and mortality from COVID-19 infection than non-cancer patients. In this study, the authors reviewed the clinical characteristics of patients with a diagnosis of cancer hospitalized with COVID-19 to assess potential correlates of COVID-19 severity in this population. Notably, analysis of the hospital data revealed a statistically significant increased incidence of mortality in cancer patients who were receiving systemic anti-cancer treatment, including chemotherapy, immunotherapy or targeted therapy, than in those not on therapy. Likewise, there was a trend toward increased mortality in those with either primary or metastatic tumor involvement of the lung compared with those without lung involvement. |
| المشرفين على المادة: | 0 (Antineoplastic Agents) 0 (Immune Checkpoint Inhibitors) 0 (Immunologic Factors) |
| تواريخ الأحداث: | Date Created: 20220202 Date Completed: 20220221 Latest Revision: 20240405 |
| رمز التحديث: | 20240405 |
| مُعرف محوري في PubMed: | PMC8809375 |
| DOI: | 10.2217/fon-2021-1116 |
| PMID: | 35105156 |
| قاعدة البيانات: | MEDLINE |
PDF full text from Publisher | تدمد: | 1744-8301 |
|---|---|
| DOI: | 10.2217/fon-2021-1116 |